STAT6 and colorectal cancer: Intratumoral or intravenous administration of exoASO-STAT6 in syngeneic tumor models of colorectal cancer and hepatocellular carcinoma (HCC), respectively, resulted in substantial tumor growth inhibition and complete tumor remission (CR) in most of the treated animals.